Caris Life Sciences Introduces Multimodal AI-Powered Molecular Insight to Identify the Benefit or Harm from the Addition of Chemotherapy for NSCLC Patients [Yahoo! Finance]
Caris Life Sciences, Inc. (CAI)
Last caris life sciences, inc. earnings: 10/29 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
investor.capps.com/investor-relations
Company Research
Source: Yahoo! Finance
IRVING, Texas April 8, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the launch of a groundbreaking AI-driven molecular insight for a subset of mono-immunotherapy eligible non-small cell lung cancer (NSCLC) patients. The NSCLC immunotherapy (IO) treatment selection signature was developed to determine which patients benefit from the addition of chemotherapy versus those who are harmed by the addition of chemotherapy. Caris Life Sciences Logo (PRNewsfoto/Caris Life Sciences) Caris Life Sciences continues to advance precision oncology by integrating multimodal real-world datasets available with its proprietary CodeAI™ platform, enabling the creation of Caris AI Insights, which utilize Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS), and clinical data to generate greater biological understanding and more actionable insights for physicians and
Show less
Read more
Impact Snapshot
Event Time:
CAI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAI alerts
High impacting Caris Life Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
CAI
News
- Caris Precision Oncology Alliance Welcomes UCSF Helen Diller Family Comprehensive Cancer Center [TheStreet.com]TheStreet.com
- Caris Precision Oncology Alliance Welcomes UCSF Helen Diller Family Comprehensive Cancer CenterPR Newswire
- Caris Life Sciences Right-In-Time Clinical Trial Solution Expands Access to Precision Oncology Trials for Historically Underserved Cancer Patients [TheStreet.com]TheStreet.com
- Caris Life Sciences Right-In-Time Clinical Trial Solution Expands Access to Precision Oncology Trials for Historically Underserved Cancer PatientsPR Newswire
- Caris Life Sciences (CAI) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating and a $28.00 price target on the stock.MarketBeat
CAI
Earnings
- 2/26/26 - Beat
CAI
Sec Filings
- 4/7/26 - Form SCHEDULE
- 4/2/26 - Form 8-K
- 3/10/26 - Form 4
- CAI's page on the SEC website